Microvascular Coronary Dysfunction in a Woman With Signs and Symptoms of Myocardial Ischemia but No Obstructive Coronary Artery Disease

Ravi S. Kahlon, Kamlesh Kothawade, Chrisandra Shufelt, Saibal Kar, Puja K. Mehta, C. Noel Bairey Merz

Abstract

Women with signs and symptoms of myocardial ischemia often have no obstructive coronary artery disease by invasive coronary angiography when compared to men. Microvascular coronary dysfunction (MCD) is thought to be a key contributory mechanism for myocardial ischemia in women with chest pain and no obstructive CAD. We report a case of a 53-year-old post-menopausal female with hyperlipidemia evaluated for persistent chest pain following a non-ST elevation myocardial infarction (NSTEMI) and no obstructive CAD by coronary angiography. Vital signs and physical examination were within normal limits. Prior EKG showed diffuse abnormal T wave inversion and flattening in anterior and inferior leads. Echocardiography demonstrated an ejection fraction of 72% with no regional wall motion abnormalities. Laboratory values revealed a positive heterozygote factor V Leiden mutation. Given the constellation of persistent chest pain, no obstructive CAD, and prior NSTEMI, a diagnosis of MCD was suspected and she underwent coronary reactivity testing (CRT) with intracoronary infusions of adenosine, acetylcholine, and nitroglycerin to test non-endothelial coronary reactivity. CRT results were consistent with a diagnosis of MCD. A statin and angiotensin converting enzyme inhibitor was added to her existing treatment of beta-blocker and nitrates. Additionally, she was started on warfarin therapy due to a positive factor V Leiden in the setting of prior NSTEMI. Her symptoms improved at one-month follow-up and she is currently asymptomatic by self-report. In women with signs and symptoms of myocardial ischemia and no obstructive CAD, it is important to identify and diagnose MCD, as inadequate diagnosis is associated with an increased risk of adverse cardiovascular events including myocardial infarction, congestive heart failure, and sudden cardiac death. Identification of MCD and clinical awareness are vital for optimal medical therapy and reduced CVD risk. Clinical trials testing efficacy of traditional and novel interventions are needed in MCD populations.

Keywords: Microvascular coronary dysfunction; Coronary reactivity testing; Non-Obstructive coronary artery disease

Introduction

Patients undergoing coronary angiography for acute coronary syndromes, including unstable angina, ST elevation and non-ST elevation myocardial infarction, often have no obstructive coronary artery disease (CAD) on invasive angiography [1]. There is a higher prevalence of no obstructive CAD in women compared to men, and women exhibit a greater symptom burden and more functional disability compared to men [2-4]. Microvascular Coronary Dysfunction (MCD) is thought to be a key contributory mechanism for myocardial ischemia in women with chest pain and no obstructive CAD. Identification of angina caused by MCD is crucial due to the associated major adverse cardiac events such as myocardial infarction, congestive heart failure, and sudden cardiac death [5, 6]. MCD as a cause of angina also contributes to poor quality of life, morbidity, and health care costs [7]. Thus, a thorough evaluation of patients with persistent chest pain is important for accurate diagnosis and treatment. Here, we present the case of a woman with persistent chest pain symptoms following a non-ST elevation myocardial infarction (NSTEMI) and no obstructive CAD documented by angiography. This case highlights the utility of coronary reactivity testing as a diagnostic tool for evaluating cardiac etiologies of persistent chest pain.

Case Report

A 53-year-old female was referred to a tertiary heart center for a second opinion and further evaluation of persistent episodes of chest pain. Her medical history was significant only for hyperlipidemia on statin therapy. She had no additional...
cardiac risk factors including no history of diabetes, hypertension, or family history of premature CAD. The patient had quit smoking 29 years prior.

Two months prior to presentation she began experiencing left arm tightness and tingling, for which she was hospitalized at an outside center. Her initial ECG showed T-wave abnormalities in an anterior-inferior distribution, with inverted T waves in V1 to V6. Troponin on this hospitalization peaked at 6.35 ng/mL and patient was transferred to an outside facility for further work-up. She underwent coronary angiography that found an LVEDP of 10 mmHg, ejection fraction of 60% with normal wall motion, and open coronary arteries. The patient was discharged home on aspirin 81 mg, clopidogrel, and pravastatin. She visited a cardiologist as an outpatient and was started on metoprolol XL.

One month prior to presentation at our facility she experienced a similar episode, with neck and back pain, and subsequently went to her nearest emergency room. Her ECG on this second visit again showed T wave abnormalities with T-wave inversions in V1 through V3, flattened T waves in V4 through V6, as well as lead III and aVF. There were no ST elevations. A resting 2-D echo showed no wall motion abnormalities and an EF of 73%. Troponin level peaked on this admission at 5.88 ng/mL and she was discharged home pain-free and scheduled for outpatient follow-up.

Six days prior to presentation, the patient was driving with her husband when she developed acute onset of neck and squeezing left arm pain with associated nausea, unrelied by ibuprofen and minimally relieved by sublingual nitroglycerin. The patient ignored the continued pain that persisted, and she was eventually seen at an outside hospital where she was found to have an elevated troponin to approximately 7 ng/mL. Patient was then transferred to a tertiary heart center for further evaluation.

On initial examination she was afebrile, with blood pressure 130/60 mmHg, pulse of 80 bpm, respirations 18, and oxygen saturation of 98% on room air. Physical exam was unremarkable. ECG and 2-D echocardiogram were unchanged from her prior hospitalization. Laboratory values were notable for a positive factor V Leiden mutation (heterozygote), and an elevated ESR of 27 mm/hr. Given the constellation of persistent chest pain, absence of obstructive CAD, and prior NSTEMI, a diagnosis of MCD was suspected. Adenosine stress MRI showed no perfusion defects and no wall motion abnormalities. The patient was discharged on her previous medications with the addition of isosorbide mononitrate 60 mg every morning.

She subsequently underwent coronary reactivity testing (CRT) with intracoronary infusions of adenosine, acetylcholine (Ach), and nitroglycerin (NTG) to test non-endothelial and endothelial micro- and macrovascular coronary function (Fig. 1, 2) (Table 1) using previously published methods [8].

Coronary angiography once again demonstrated no evidence of obstructive coronary disease. The right coronary was small with possible scalloping suggestive of luminal irregularities consistent with atherosclerosis. Left ventricular end diastolic filling pressure was elevated at 18 mmHg. CRT was markedly abnormal, with an abnormal coronary flow reserve to intracoronary adenosine at 2.3 (normal is greater than 2.5), and abnormal coronary endothelial function response to acetylcholine with 60% vasoconstriction (normal response is positive dilation). Microvascular endothelial coronary blood flow was calculated to be abnormal at 62% decrease in response to Ach (normal response is greater than 50% increase). There was a normal nitroglycerin response, consistent with normal smooth muscle function of 38% dilation (normal response is greater than 20%). CRT results were consistent with a diagnosis of MCD. The patient was continued on her beta-blocker and nitrates. Given endothelial dysfunction, an ACE inhibitor and a statin were added to her regimen. Due to her positive factor V Leiden and recurrent NSTEMIs she was transitioned from aspirin to warfarin therapy.

Four months later, the patient presented to a community...
hospital after experiencing nausea and vomiting, and chest pain unrelieved by nitroglycerin. She was found to have a troponin peak of 6.5 ng/mL and INR of 3.2 on admission. Patient was started on a nitroglycerin drip for her persistent chest pain and elevated troponins. After transfer to a facility providing higher-level care, she became stable and chest pain free. Again troponins were down trending, and vital signs, examination, and laboratory values were within normal limits. The patient underwent repeat coronary angiography that showed no obstructive coronary disease, normal LVEDP (8 mmHg), and normal EF (73%), but was noted to have vasospasm of the right coronary ostium during the procedure with a drop in pressure suggestive of a vasospastic response. Endomyocardial biopsy was performed and was negative for myocarditis or an infiltrative process such as sarcoid or amyloid. Given that vasculitis was a possible cause of persistent troponin elevation, she received a vascular workup, including anticardiolipin IgA and IgM, which were negative, and complement C3, C4 levels, which were within normal limits. Similarly, ANA was undetectable. A Russell viper venom and lupus anticoagulant were both negative.

The patient was discharged in stable condition with phase II cardiac rehab and the following changes in her medication regimen. Her beta-blocker was switched to Cardizem given the ostial spasm seen on angiography. She was started on Ranolazine 500 mg twice daily given non-obstructive CAD, presence of MCD, and refractory pain with nitroglycerin. Warfarin was switched back to low-dose aspirin given that her heterozygous factor V Leiden had not produced a thrombotic event, and the coronary protective effects of aspirin. The patient’s symptoms were improved at 1-month follow-up, and she is currently asymptomatic by self-report.

**Discussion**

The etiology of persistent chest pain is not only difficult,
but also encompasses a broad array of diagnoses. Too often, once coronary angiography reveals normal or open coronary arteries and patients are usually reassured and discharged with the diagnosis of non-cardiac chest pain without further cardiac evaluation. This can lead to adverse effects on quality of life, morbidity, and cost of healthcare. Eighty percent of patients with continued chest pain and no evidence of CAD were found to have chest pain at least weekly for up to one year post-angiogram, with unchanged or even worsening pain, and with half reporting functional disability including limitations on activities of daily living and/or inability to work [9, 10]. Despite open coronary angiograms, twenty to fifty percent of patients are re-hospitalized for chest pain with an average lifetime cost per patient set at approximately eight hundred thousand dollars [7].

Approximately 50% of women with symptoms of persistent chest pain, evidence of ischemia, and presence of no obstructive CAD have been found to have MCD [11]. The Women’s Ischemia Syndrome Evaluation (WISE) study group has shown that MCD is prevalent in women with the triad of chest pain, evidence of ischemia by stress testing, and non-obstructive CAD [12]. These women tend to be younger with mean ages in the fifth decade of life (range 21 - 86 years) [2-4, 6]. The diagnosis of MCD is challenging because the coronary microvasculature is not directly visualized during routine coronary angiography. It is the microvasculature however, which is responsible for coronary blood flow regulation and therefore oxygen delivery. Autoregulation involves both endothelial dependent and independent mechanisms. Coronary endothelial dysfunction is an indicator of early atherosclerosis [13] and is independently associated with cardiovascular events [5, 6]. Patients with coronary endothelial dysfunction and non-obstructive CAD have an increased risk of fatal and non-fatal major adverse cardiac events including sudden cardiac death, myocardial infarction, and congestive heart failure [5, 6, 8]. The above case illustrates that although the patient had no detectable ischemia on stress testing, this likely reflects the low sensitivity of the diagnostic modality and not the absence of ischemia, and the cause of her persistent chest pain is, at least in part, due to MCD.

During CRT four measures of coronary vascular autoregulation are assessed: 1) coronary flow reserve (CFR) in response to intracoronary administration of adenosine as an indicator of non-endothelial microvascular function [14]; 2) coronary blood flow (CBF) indicative of endothelial microvascular function; 3) coronary artery diameter in response to intracoronary administration of acetylcholine as measured by quantitative coronary angiography (QCA) an indicator of endothelial macrovascular function; and 4) coronary artery diameter in response to intracoronary nitroglycerin as measured by QCA indicative of non-endothelial macrovascular function. Data regarding the safety of CRT has found that this diagnostic modality is at least equal to routine coronary angiogram with approximately 1 in 1,000 risk of serious adverse events [15, 16]. Moreover, because the risk of fatal and non-fatal major adverse cardiac events associated with endothelial dysfunction [5, 6, 8, 17], and MCD [17, 18] is high (up to 2.5%) compared with the risk of serious and/or adverse events with CRT [15, 16] (0.7%), patients with the triad of persistent chest pain, objective evidence of myocardial ischemia, and no obstructive CAD should be considered for CRT when the diagnosis is uncertain.

Treatment of MCD can also be challenging due to a lack of universally accepted diagnostic criteria and multiple pathways contributing to the pathophysiology. Goals, as with therapy for obstructive CAD, include controlling debilitating symptoms, improving quality of life, reducing hospitalization incidence and repeat testing, and improving survival. Cardiac rehabilitation can be initiated to minimize symptoms and has been shown to be effective in these patients in increasing exercise capacity and symptom relief [19]. Statins may improve endothelial function by lipid-independent mechanisms through their anti-inflammatory and anti-oxidant properties, or like ACEIs and ARBs, through their ability to restore vascular nitric oxide and thus endothelial-dependent relaxation of coronary resistance vessels [20-22]. Beta blockade, particularly with atenolol, has been shown to reduce the number and severity of anginal episodes and improve functional capacity in patients with MCD [23]. Additional benefit may be seen from agents with alpha-blockade, such as carvedilol, in patients with coronary spasm [24]. Recently, a pilot study of Ranolazine, an anti-anginal agent that reduces calcium flow in myocytes through inhibition of the late sodium current, has been shown to improve angina in women with evidence of ischemia but no obstructive CAD [25]. While there are no clinical trials regarding the role of nitrates in patients with MCD, at least observationally, their effects on angina frequency and duration can be unpredictable in these patients. Similarly, the use of calcium channel blockers for management of MCD is not yet supported by evidence, although it is first line therapy for vasospastic angina and has been shown to improve exercise capacity and chest pain in patients with no obstructive CAD and limited vasodilatory reserve [26].

In conclusion, this case highlights the clinical importance and challenges of diagnosing MCD. In women with signs and symptoms of myocardial ischemia, NSTEMI, and no obstructive CAD, MCD may be a mechanism leading to symptoms. It is therefore important to identify and diagnose in the appropriate clinical setting, as MCD is associated with an increased risk of adverse cardiovascular events. Moreover, MCD is the presumable cause of symptoms that can lead to repeated testing, hospitalization, and disability, creating substantial economic, physical, and emotional hardships [7]. It is imperative that clinicians are aware of this condition, as early identification of MCD by CRT in the appropriate clinical setting may be beneficial in prognostication and/or stratification of these patients for optimal medical therapy.
Grant Support

This work was supported by contracts from the National Heart, Lung and Blood Institute, nos. N01-HV-68161, N01-HV-68162, N01-HV-68163, N01-HV-68164, grants U0164829, U01 HL649141, U01 HL649241, T32HL69751, 1R03AG032631 from the National Institute on Aging, GCRC grant MO1-RR00425 from the National Center for Research Resources, NIH CTSI Grant UL1TR000124 and grants from the Gustavus and Louis Pfeiffer Research Foundation, Danville, NJ, The Women’s Guild of Cedars-Sinai Medical Center, Los Angeles, CA, The Ladies Hospital Aid Society of Western Pennsylvania, Pittsburgh, PA, and QMED, Inc., Laurence Harbor, NJ, the Edythe L. Broad Women’s Heart Research Fellowship, Cedars-Sinai Medical Center, Los Angeles, California, and the Barbra Streisand Women’s Cardiovascular Research and Education Program, Cedars-Sinai Medical Center, Los Angeles.

Disclosures

There are no relevant conflicts of interest of any of the authors to disclose.

References


17. Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, Johnson BD, et al. Insights from the NHL-


